Vrati se na sadržaj

Pređi na pomoćni meni

Jehovini svedoci

srpski (latinica)

Hematologija (onkologija)

Kontrolisanje i optimizacija hemostaze

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series.

Marshall A, Li A, Drucker A, Dzik W

Izvor‎: Hematol Oncol 2016;34(3):147-53.

Indeks‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

http://www.ncbi.nlm.nih.gov/pubmed/25641349

Alternatives to allogeneic platelet transfusion.

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ

Izvor‎: Br J Haematol 2016;175(3):381-92.

Indeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

http://www.ncbi.nlm.nih.gov/pubmed/27650431

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.

Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, Obermann-Slupetzky O, Chapman M, Fritsch S, Pavlova BG, Presch I, Ewenstein B

Izvor‎: Blood 2015;126(17):2038-46.

Indeks‎: PubMed 26239086

DOI‎: 10.1182/blood-2015-02-629873

http://www.ncbi.nlm.nih.gov/pubmed/26239086

Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis.

Berkhof FF, Eikenboom JC.

Izvor‎: Transfusion 2009;49(3):570-7.

Indeks‎: PubMed 19040498

DOI‎: 10.1111/j.1537-2995.2008.02001.x

http://www.ncbi.nlm.nih.gov/pubmed/19040498

Tranexamic acid in oncology.

Seto AH, Dunlap DS.

Izvor‎: Ann Pharmacother 1996;30(7-8):868-70.

Indeks‎: PubMed 8826574

http://www.ncbi.nlm.nih.gov/pubmed/8826574

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts.

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B.

Izvor‎: Br J Haematol 2013;160(2):228-36.

Indeks‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

http://www.ncbi.nlm.nih.gov/pubmed/23151086

Postpartum hemorrhage: when uterotonics and sutures fail.

James AH, McLintock C, Lockhart E.

Izvor‎: Am J Hematol 2012;87 Suppl 1:S16-22.

Indeks‎: PubMed 22430921

DOI‎: 10.1002/ajh.23156

http://www.ncbi.nlm.nih.gov/pubmed/22430921

Bronchoscopic intratumoral injection of tranexamic acid: a new technique for control of biopsy-induced bleeding.

Zamani A.

Izvor‎: Blood Coagul Fibrinolysis 2011;22(5):440-2.

Indeks‎: PubMed 21577092

DOI‎: 10.1097/MBC.0b013e328346efb7

http://www.ncbi.nlm.nih.gov/pubmed/21577092

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review.

Franchini M, Veneri D, Lippi G.

Izvor‎: Bone Marrow Transplant 2007;39(12):729-35.

Indeks‎: PubMed 17417659

http://www.ncbi.nlm.nih.gov/pubmed/17417659

Transcutaneous arterial embolization to control massive tumor bleeding in head and neck cancer: 63 patients' experiences from a single medical center.

Chou WC, Lu CH, Lin G, Hong YS, Chen PT, Hsu HC, Chen JS, Yeh KY, Wang HM, Liaw CC.

Izvor‎: Support Care Cancer 2007;15(10):1185-90.

Indeks‎: PubMed 17356807

http://www.ncbi.nlm.nih.gov/pubmed/17356807

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage.

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Izvor‎: Cancer 2006;107(1):136-40.

Indeks‎: PubMed 16708357

http://www.ncbi.nlm.nih.gov/pubmed/16708357

Management of bleeding in patients with advanced cancer.

Pereira J, Phan T.

Izvor‎: Oncologist 2004;9(5):561-70.

Indeks‎: PubMed 15477642

http://www.ncbi.nlm.nih.gov/pubmed/15477642

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.

Gerotziafas GT, Zervas C, Gavrielidis G, et al.

Izvor‎: Am J Hematol 2002;69(3):219-22.

Indeks‎: PubMed 11891811

http://www.ncbi.nlm.nih.gov/pubmed/11891811


Deo s medicinskim informacijama na sajtu jw.org namenjen je prvenstveno lekarima specijalistima i drugim zdravstvenim radnicima. On ne sadrži medicinske savete niti preporuke za određeno lečenje i nije zamena za konsultovanje sa stručnim zdravstvenim radnikom. Medicinsku literaturu koja se ovde navodi nisu izdali Jehovini svedoci, ali u njoj se govori o strategijama beskrvnog lečenja koje se mogu uzeti u obzir. Svaki medicinski radnik je odgovoran da bude u toku s novim informacijama, razmotri više načina za pružanje medicinske nege i da pomogne pacijentima da donesu odluku koja je u skladu s njihovim medicinskim stanjem, željama, merilima i verovanjima. Nisu sve ovde navedene strategije primenjive i prihvatljive za sve pacijente.

Za pacijente: Uvek se konsultujte s vašim lekarom ili drugim kvalifikovanim zdravstvenim radnikom u vezi s vašim medicinskim stanjem i lečenjem. Ako smatrate da imate zdravstvenih problema, obratite se lekaru.

Korišćenje ovog veb-sajta propisano je pravilima korišćenja.